In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

However, for many people, hair loss can be an exhausting experience, typically caused by underlying medical concerns. Among these, autoimmune diseases play a significant role. These conditions ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

The lifetime risk of alopecia areata expression in the general population has been estimated to be 1.7%. [19] The disease starts with a single patch of hair loss, preferably on the scalp or in the ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...

scarring and irreversible hair loss. The disease affects an increasing number of patients worldwide and is caused by genetic and environmental factors. The study authors conducted a meta-analysis ...

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing ...

Losing 50-100 strands per day is a normal phenomenon and nothing to be worried about but when this number increases, you must take it as a warning sign as you could be suffering from hair loss.

Androgenetic alopecia is the most common cause of hair loss in men and women (50%-80% of postpubertal whites). In men, a recession of the hairline in the frontoparietal region is observed ...